Picture of BillionToOne logo

BLLN — BillionToOne News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

BillionToOne poised to open 33% above offer price in Nasdaq debut

** Molecular diagnostics firm BillionToOne's BLLN.O shares were poised to open 33.3% above their offer price in their Nasdaq debut

** Stock indicated to open at $80 apiece vs $60 IPO price

** BLLN sold 4.56 million shares in an upsized IPO to raise $273.1 million

** Menlo Park, California-based BLLN had initially marketed 3.85 million shares between $49 and $55 apiece

** BLLN develops molecular diagnostic tests — including a non-invasive prenatal screen and liquid biopsy — for various diseases

** In the six months ended June 30, BLLN's revenue surged 82% to $125.5 million, while net loss narrowed to $4.2 million

** J.P. Morgan, Piper Sandler, Jefferies and William Blair were joint book-running managers for the offering

 (Reporting by Arasu Kannagi Basil in Bengaluru)

 ((ArasuKannagi.Basil@thomsonreuters.com;))

Recent news on BillionToOne

See all news